This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Lifshitz & Miller Law Firm Announces Investigation Of Emeritus Corporation, Nu Skin Enterprises, Inc., The Medicines Company, Thoratec Corporation And TriQuint Semiconductor, Inc.

NEW YORK, Feb. 26, 2014 /PRNewswire/ --

Emeritus Corporation

Lifshitz & Miller announces an investigation into possible breaches of fiduciary duty in connection with the proposed sale of Emeritus Corporation ("Emeritus") (ESC) to Brookdale Senior Living Inc. for 0.95 shares of Brookdale common stock or transaction value totaling $2.8 billion, with the inclusion of $1.4 billion of Emeritus mortgage debt.

Lifshitz & Miller's investigation is focused on whether the Emeritus directors are acting in shareholders' best interest.

For more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at (516) 493-9780 or by sending an e-mail including your contact information to: info@jlclasslaw.com.

Nu Skin Enterprises, Inc.

Lifshitz & Miller  announces that a class action was filed in the United States District Court for the District of Utah, alleging that Nu Skin Enterprises, Inc. ("Nu Skin") (NUS) issued false and misleading statements to investors between July 10, 2013 through January 16, 2014 by failing to disclose that the Company's operations in the People's Republic of China ("PRC") resulted in pyramid selling schemes in violation of PRC law.

For more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at (516) 493-9780 or by sending an e-mail including your contact information to: info@jlclasslaw.com.

The Medicines Company

Lifshitz & Miller  announces that a class action was filed in the United States District Court for the District of New Jersey, alleging that The Medicines Company ("Medicines") (MDCO) issued false and misleading statements to investors between February 20, 2013 and February 12, 2014, inclusive by failing to disclose that the Company's clinical trials for Cangrelor were unethically and inappropriately administered.

For more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at (516) 493-9780 or by sending an e-mail including your contact information to: info@jlclasslaw.com.

Thoratec Corporation

Lifshitz & Miller  announces that a class action was filed in the United States District Court for the Northern District of California, alleging that Thoratec Corporation ("Thoratec") (THOR) issued false and misleading statements to investors between April 29, 2010 and November 27, 2013, inclusive by failing to disclose that Company's HeartMate II Left Ventricular Assist Device had significant risk of pump thrombosis causing numerous fatalities.

For more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at (516) 493-9780 or by sending an e-mail including your contact information to: info@jlclasslaw.com.

TriQuint Semiconductor, Inc.

Lifshitz & Miller announces an investigation into possible breaches of fiduciary duty in connection with the proposed sale of TriQuint Semiconductor, Inc. ("TriQuint") (TQNT) to RF Micro Devices, Inc. in a stock transaction with an implied price of $9.73 for each TriQuint share.

Lifshitz & Miller's investigation is focused on whether the proposed deal provides adequate value to TriQuint shareholders.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs